Clovis Oncology is a biopharmaceutical company focused on acquiring, developing and commercializing cancer treatments in the United States, Europe and other international markets. Our product development programs target specific subsets of cancer, and we seek to simultaneously develop, with partners, companion diagnostics that direct our product candidates to the patients most likely to benefit from their use. We believe this approach to personalized medic
New rucaparib data to be highlighted in poster presentations
Rolling New Drug Application (NDA) submission for rucaparib for the
treatment of patients with advanced ovarian cancer expected to
complete during Q2 2016
European Marketing Authorization Application (MAA) planned in Q4
BOULDER, Colo.--(BUSINESS WIRE)--May 19, 2016--
Clovis Oncology, Inc. (NASDAQ: CLVS) today announced its presen...
Rucaparib rolling NDA submission initiated for treatment of
patients with advanced ovarian cancer with deleterious BRCA mutated
tumors and expected to complete Q2 2016
Rucaparib MAA submission planned Q4 2016
Clovis preparing for potential U.S. commercial launch of rucaparib
with existing commercial infrastructure in Q4 2016 or Q1 2017
ARIEL3 pivotal rucaparib maintenance study target enrollment...
BOULDER, Colo.--(BUSINESS WIRE)--Apr. 26, 2016--
Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its first quarter
2016 financial results on Thursday, May 5, 2016, after the close of the
U.S. financial markets. Clovis’ senior management will host a conference
call and live audio webcast at 4:30 p.m. ET that day to discuss the
company’s results in greater detail.
The conference call is being webcast and can be accessed from the Clovis
Sign up to receive email alerts whenever Clovis Oncology, Inc. posts new information to the site. Just enter your email address and click Submit.
Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.